Page last updated: 2024-09-04

pomalidomide and pevonedistat

pomalidomide has been researched along with pevonedistat in 1 studies

Compound Research Comparison

Studies
(pomalidomide)
Trials
(pomalidomide)
Recent Studies (post-2010)
(pomalidomide)
Studies
(pevonedistat)
Trials
(pevonedistat)
Recent Studies (post-2010) (pevonedistat)
62312155229911289

Protein Interaction Comparison

ProteinTaxonomypomalidomide (IC50)pevonedistat (IC50)
Ubiquitin-like modifier-activating enzyme 6Homo sapiens (human)1.8
Ubiquitin-like modifier-activating enzyme 1 Mus musculus (house mouse)1.5
NEDD8-activating enzyme E1 regulatory subunitHomo sapiens (human)0.0471
NEDD8Homo sapiens (human)0.0047
NEDD8-activating enzyme E1 catalytic subunitHomo sapiens (human)0.0033
SUMO-activating enzyme subunit 1Homo sapiens (human)8.2
SUMO-activating enzyme subunit 2Homo sapiens (human)8.2

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y1

Reviews

1 review(s) available for pomalidomide and pevonedistat

ArticleYear
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases

2022